BriefCase-Quantification vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

BriefCase-Quantification

by Aidoc Medical

EchoNext

by Pathway Labs

AI Verdict

Both Aidoc's BriefCase-Quantification and Pathway Labs' EchoNext are FDA-cleared AI tools in the cardiology AI category, but they address different diagnostic stages and data types. BriefCase-Quantification focuses on automated abdominal aortic diameter measurements from CT scans for radiologists, aiding in the quantification of known or suspected vascular conditions. In contrast, EchoNext analyzes standard ECGs to detect hidden structural heart disease, offering a non-invasive screening tool for a broader range of cardiac conditions earlier in the diagnostic pathway.

Choose BriefCase-Quantification if…

Choose BriefCase-Quantification if your radiology department needs an AI tool to automatically measure abdominal aortic diameters from CT scans, aiming to streamline workflows and assist radiologists with quantitative measurements. This tool is ideal for facilities focused on efficient radiological image management and processing for conditions like abdominal aortic aneurysms.

View BriefCase-Quantification →

Choose EchoNext if…

Choose EchoNext if your practice or hospital aims to implement a non-invasive, AI-powered screening tool to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard ECGs. This tool is particularly beneficial for early detection and identifying high-risk patients who may require further cardiac evaluation.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	BriefCase-Quantification	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Cloud-based	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoNext

EchoNext is deployed through the OpenEvidence clinical decision support platform, which is widely used by over 750,000 verified clinicians in the U.S. and is designed to integrate into existing workflows, making it highly accessible and potentially easier to adopt for many practitioners. Aidoc's BriefCase-Quantification integrates with PACS and EHR systems, but EchoNext's broad platform deployment suggests a wider immediate reach and potentially lower barrier to entry for many users.

Clinical Value

EchoNext

EchoNext analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, with reported higher accuracy than cardiologists, even those with AI assistance. This offers a novel, non-invasive screening method for conditions often undiagnosed until symptomatic. BriefCase-Quantification provides automated abdominal aortic diameter measurements, which is valuable for clinical decision-making, but EchoNext's ability to detect multiple, often-missed structural heart diseases from a common test presents a broader clinical impact.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, including an annual discount option and add-ons for premium features, making its cost structure clear to potential users. BriefCase-Quantification requires contacting for pricing, which suggests a less transparent, potentially more complex, and variable pricing model.

Enterprise Readiness

BriefCase-Quantification

Aidoc's BriefCase-Quantification is part of Aidoc's aiOSu2122 enterprise AI platform, which is designed to scale clinical AI across health systems, unifying data, workflows, and oversight. This platform approach, with its focus on governance, continuous performance monitoring, and integration with PACS and EHR, demonstrates a strong emphasis on enterprise-level deployment and management. While EchoNext is available through the OpenEvidence platform, Aidoc's explicit focus on an 'AI Operating System' for enterprise-wide adoption gives it an edge in readiness for large-scale health systems.

Innovation

EchoNext

EchoNext represents a significant innovation by enabling the detection of multiple structural heart diseases from a standard 12-lead ECG, a test not traditionally used for such diagnoses. This capability addresses a critical gap in early detection for cardiovascular disease, which is the leading cause of death globally. BriefCase-Quantification's automated measurements are valuable, but EchoNext's ability to derive novel diagnostic insights from existing, widely available data pushes the boundaries of current diagnostic capabilities.

Support & Docs

Tie

Both tools are FDA-cleared and operate within regulated healthcare environments, implying a baseline level of documentation and support. However, specific details regarding the breadth and depth of their support resources, such as dedicated customer service teams, comprehensive user manuals, or online knowledge bases, are not provided in the given information for either tool. Therefore, it is not possible to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	BriefCase-Quantification	EchoNext
Name	BriefCase-Quantification	EchoNext
Company	Aidoc Medical	Pathway Labs
Description	FDA-cleared AI tool for radiologists, providing automated abdominal aortic diameter measurements from CT scans to assist clinical decision-making and streamline workflows.	FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features	Automated abdominal aortic diameter measurement, Radiological image management and processing, Integration with image review software, Cloud-based deployment, Assists medical specialists with quantitative measurements, Part of Aidoc's aiOSu2122 enterprise AI platform, Supports streamlined clinical workflows	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support
Specialties	Cardiology, Radiology, Vascular Surgery	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring BriefCase-Quantification and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools fit into existing clinical workflows for cardiology and radiology?

BriefCase-Quantification is designed to integrate into radiology workflows by analyzing CT scans and sending automated abdominal aortic diameter measurements to image review software and PACS, assisting radiologists and vascular surgeons. EchoNext integrates into cardiology and primary care workflows by analyzing standard ECGs to identify patients at high risk for structural heart disease, helping to determine who should proceed to an echocardiogram. It is available through the OpenEvidence clinical decision support platform, which is used by many physicians.

What is the depth of EHR integration for each tool?

BriefCase-Quantification processes filtered DICOM images and exports the analysis results in DICOM format to a PACS destination for review by medical specialists. EchoNext is available through the OpenEvidence clinical decision support platform, which suggests a level of integration for accessing the tool's insights within a broader clinical context.

What are the accuracy and sensitivity metrics for each tool in detecting relevant conditions?

BriefCase-Quantification demonstrated a sensitivity of 92.7% and specificity of 92.8% in detecting abdominal aortic dissection. For other triage applications, Aidoc's AI solutions have achieved a mean sensitivity of 97% and a mean specificity of 98% across 11 indications in an FDA-reviewed study. EchoNext has shown high accuracy, with an AUROC of 85.2% in internal tests and 78-80% in external validation for detecting structural heart disease. In a head-to-head comparison, EchoNext achieved 77% accuracy in identifying structural heart problems from ECGs, compared to 64% for cardiologists without AI assistance.

What is the learning curve for physicians to effectively use these AI tools?

BriefCase-Quantification is intended to assist appropriately trained medical specialists by providing automated measurements, suggesting it augments existing workflows rather than requiring extensive new interpretation skills. EchoNext analyzes standard 12-lead ECGs, a familiar diagnostic tool for cardiologists and other physicians, and provides risk scores to guide further imaging, potentially streamlining the learning curve for its integration into clinical decision-making.

What kind of customer support and resources are available for implementation and ongoing use?

Aidoc emphasizes a strong Quality Management System that governs all stages of its product lifecycle, aiming to deliver reliable medical software. They also provide regulatory affairs support to ensure products are authorized in relevant regions. For EchoNext, the partnership with OpenEvidence aims to facilitate broad access and integration into existing physician tools, suggesting support for deployment and use within that platform.

What are the considerations for rolling out these tools across multiple clinical sites or a large health system?

Aidoc's aiOSu2122 enterprise AI platform is designed to sustain AI performance and impact at foundation-model scale through data normalization, continuous performance monitoring, and built-in governance, enabling health systems to deploy and manage multi-condition clinical AI without re-architecting infrastructure. EchoNext's generalizability has been demonstrated across diverse patient demographics, clinical contexts, and numerous hospitals, and its availability through the OpenEvidence platform aims to facilitate widespread adoption across various practice settings.

Can these tools provide audit trails or detailed logging of AI-driven analyses and physician interactions?

While specific audit-trail features are not detailed for either tool, Aidoc's commitment to a robust Quality Management System and compliance with regulations like FDA's Quality System Regulation (21 CFR Part 820) and ISO 13485:2016 suggests a focus on traceability and accountability in their software development and operation. Similarly, as a medical device, EchoNext would likely adhere to regulatory expectations for data integrity and accountability, though specific audit trail functionalities are not explicitly mentioned.